abstract |
Sulfonamide derivatives as BCL‑2‑selective apoptosis-inducing agents for the treatment of cancer and immune diseases. Compounds that inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which anti-apoptotic Bcl-2 proteins are expressed are disclosed. |